dsm-firmenich introduces GLYCARE® SK range Kaiseraugst, Switzerland; 19% TEWL reduction, 38% redness drop

dsm-firmenich introduces GLYCARE® SK range Kaiseraugst, Switzerland; 19% TEWL reduction, 38% redness drop dsm-firmenich introduces GLYCARE® SK range: HMO biotechnology for skin regeneration and resilience Press Release May 1, 2026 Kaiseraugst, Switzerland. May, 1 2026 Modern skin is caught in a cycle of sensitivity. In today’s world, constant exposure to UV radiation, pollution and aesthetic procedures can weaken the skin’s barrier and cause dysbiosis triggering inflammation and redness. When resilience is compromised, skin falls behind. In contrast, skin that can adapt, restore balance and recover efficiently remains healthy-looking for longer. To address this growing challenge, dsm-firmenich brings a new frontier of biotechnology to skincare with GLYCARE® SK range, powered by Human Milk Oligosaccharide (HMO) technology, — a science that has already been recognized with a scientific award at PCHi China 2026. Remarkable strength is born in the very first moments of life. Human Milk Oligosaccharides (HMOs) are unique sugar molecules naturally present in mother’s milk. They program the resilience that equips newborns to adapt, recover, and thrive. “Our expertise in HMO is built on decades of research in human nutrition,” said Mathieu Moulin, Senior Global Marketing Manager Skin Care at dsm-firmenich. “With GLYCARE® SK, we are extending this deep scientific knowledge into skincare, translating life-inspired biology into innovative solutions designed to support skin resilience and regeneration.” At dsm-firmenich, nature’s blueprint has been translated into powerful skincare solutions through advanced biotechnology. Using precision fermentation, the company replicates the exact bioidentical structures found in mother’s milk — without any human-derived materials — enabling the benefits of HMOs to be applied in cosmetic formulations. “By translating HMO biology into skincare, we can help activate the skin’s natural regenerative processes, strengthen the skin barrier, enhance resilience to inflammation and support smart microbiome adhesion,” said Martin Pagac Ph.D., Global Senior Scientist at dsm-firmenich. The result is GLYCARE® SK, a biotechnology range designed to support skin regeneration and resilience with targeted modulation of microbiome adhesion, offering a new approach for sensitive and stressed skin. Two complementary solutions address different skin needs GLYCARE® SK RENEW, the repair specialist, supports barrier recovery and skin regeneration. Advanced protocol clinically tested on individuals with chronic rosacea and sensitive skin it delivered a 19% reduction in TEWL* versus placebo confirming barrier repair and reinforcement and 38% reduction in visible redness and erythema after 8 weeks. The ingredient also restored skin structure with 7% improvement in elasticity after 4 weeks, supported by 67% collagen I stimulation observed in vitro. GLYCARE® SK COMFORT focuses on everyday resilience for sensitive skin. Clinical testing demonstrated 16% reduction in TEWL* versus placebo after 8 weeks, a 13% increase in hydration after 4 weeks, and a visible reduction in redness, helping prevent flare-ups. *TEWL: Transepidermal Water Loss. “This unique HMO innovation builds on dsm-firmenich’s long-standing leadership in biotechnology and skin science,” Mathias Gempeler Ph.D., Global Head Science & Promotion Skin Care at dsm-firmenich. With GLYCARE® SK range, dsm-firmenich continues to advance biotechnology-driven skincare innovation, bringing life-inspired science to formulations designed to meet modern expectations across global markets. GLYCARE® SK Resilience born in life’s first moments About dsm-firmenich As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss company with dual headquarters in Kaiseraugst, Switzerland and Maastricht, Netherlands, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com Beauty & Care LinkedIn | X | Instagram | Facebook For more information Global Marketing Communications Beauty & Care dsm-firmenich beautycare.communications@dsm-firmenich.com Forward-looking statements This press release may contain forward-looking statements with respect to dsm-firmenich’s future performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance, transaction progress and positions to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.

May 2, 2026

Mark Dawson Leiter Roche Pharma Forschung und Frühe Entwicklung (pRED) Basel; seit 2025

Mark Dawson Leiter Roche Pharma Forschung und Frühe Entwicklung (pRED) Basel; seit 2025 Roche | Prof. Dr. Mark Dawson Leiter Roche Pharma Forschung und Frühe Entwicklung (pRED) (Mitglied der erweiterten Konzernleitung seit 2026) 1993–1999Universität Melbourne, Bachelor of Medicine, Bachelor of Surgery (MBBS) 1999Universität Melbourne, Bachelor of Medical Science (BMedSci.) 2003–2007Fellowship of Royal Australasian College of Physicians (FRACP) 2003–2007Fellowship of Royal College of Pathologists of Australasia (FRCPA) 2007–2009Universität Cambridge, Promotion in Molekularbiologie (PhD) ...

May 1, 2026

Mikron Automation and 3P innovation announce strategic partnership for integrated DPI manufacturing in Warwick, UK and Boudry, Switzerland; 7,200 doses per minute throughput

Mikron Automation and 3P innovation announce strategic partnership for integrated DPI manufacturing in Warwick, UK and Boudry, Switzerland; 7,200 doses per minute throughput Mikron Automation and 3P innovation announce strategic partnership for integrated DPI manufacturing solution | Mikron Group Mikron Automation and 3P innovation announce strategic partnership for integrated DPI manufacturing solution Warwick, UK and Boudry, Switzerland, April 29, 2026-3P innovation, an international automation company specialising in high-precision liquid and powder drug filling systems, andMikron Automation, a developer of advanced assembly solutions for devices, today announce a long-term strategic partnership for an integrated Dry Powder Inhaler (DPI) manufacturing solution. ...

May 1, 2026

Corinna Rüffer Kassenzulassung des nicht-invasiven Pränataltests – Monitoring der Konsequenzen Berlin Paul-Löbe-Haus Saal E 300; Einrichtung eines Gremiums angekündigt

Corinna Rüffer Kassenzulassung des nicht-invasiven Pränataltests – Monitoring der Konsequenzen Berlin Paul-Löbe-Haus Saal E 300; Einrichtung eines Gremiums angekündigt 041 06 05 2026 Tagesordnung Wahlperiode Ausschuss für Gesundheit Wahlperiode Seite 1 von 2 Mitteilung Berlin, den 28. April 2026 Die 41. Sitzung des Ausschusses für Gesundheit findet statt am Mittwoch, dem 6. Mai 2026, 11:00 Uhr als Kombination aus Präsenzsitzung (Paul-Löbe-Haus, Saal E 300) und Zoom-Meeting*. *Die Zugangsdaten zum Zoom-Meeting werden an den entsprechenden Personenkreis versandt. Sekretariat Telefon: +49 30 227-32407 ...

April 30, 2026

Patent Medical stellt Symbionic Teeth in Wien vor; Langzeitstudien: keine Periimplantitis

Patent Medical stellt Symbionic Teeth in Wien vor; Langzeitstudien: keine Periimplantitis Zürcher Handelskammer: Patent Medical stellt Symbionic Teeth in Wien vor Patent Medical stellt Symbionic Teeth in Wien vor Wien - Patent Medical hat beim International Osteology Symposium 2026 in Wien mit Symbionic Teeth seine Weiterentwicklung klassischer Zahnimplantate präsentiert. Demnach belegen Forschungsarbeiten an der Universität Bern und Langzeitstudien, dass sie Periiplantitis vollständig verhindern. (CONNECT)Patent Medicalaus Altendorf hat beim diesjährigen Osteology Kongress der in Root LU ansässigenOsteology Stiftung, der vom 23. bis 25. April in Wien stattgefunden hat, ein Corporate Symposium zu seinem Zahnersatz der nächsten Generation namensSymbionic Teethveranstaltet. Geleitet wurde das nach einerMitteilungvollbesetzte Symposium von den beiden Schweizer Experten Prof. Dr. Dr. Anton Sculean, dem Direktor derKlinik für Parodontologiean derUniversität Bern, und Dr. Roland Glauser, zertifizierter Fachmann für Orale Implantologie und Inhaber der Zahnklinikcosmodentin Zürich. ...

April 30, 2026

Baden-Württemberg startet EU-Mercosur-Abkommen in Südamerika am 1. Mai 2026; Zölle sinken, bessere Chancen und Investitionen für KMU

Baden-Württemberg startet EU-Mercosur-Abkommen in Südamerika am 1. Mai 2026; Zölle sinken, bessere Chancen und Investitionen für KMU Start des EU-Mercosur-Abkommens: Baden-Württemberg.de Am 1. Mai 2026 startet das EU-Mercosur-Abkommen. Das Freihandelsabkommen mit Südamerika ist ein wichtiger Meilenstein, um Märkte breiter aufzustellen, Lieferketten widerstandsfähiger zu machen und internationale Partnerschaften zu vertiefen. Mit dem Start desEU-Mercosur-Abkommensam 1. Mai eröffnen sich für die baden-württembergische Wirtschaft zusätzliche Perspektiven in Südamerika. Das Abkommen der Europäischen Union mit Brasilien, Argentinien, Paraguay und Uruguay verbessert die Rahmenbedingungen für Handel, Investitionen und wirtschaftliche Kooperationen mit einer Region, die für den Südwesten von großer Bedeutung ist, bislang noch deutliches Entwicklungspotenzial bietet. ...

April 30, 2026

Japanese adults with myelofibrosis receive pelabresib add-on to ruxolitinib in Japan

Japanese adults with myelofibrosis receive pelabresib add-on to ruxolitinib in Japan Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis | Novartis Study Description This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF). This study consists of three periods: screening, treatment, and follow-up. After a screening period of up to 28 days, between three and nine eligible and evaluable participants will be enrolled to receive pelabresib in addition to a stable dose of ruxolitinib. The follow-up phase includes a 30-day safety follow-up and a long-term follow-up. Pelabresib will be administered until one of the following occurs: disease progression, unacceptable toxicity, death, participant decision, or investigator decision. After discontinuation of pelabresib, safety assessments will continue with a safety follow-up visit 30 days after the last dose of pelabresib. Participants will then be contacted for long-term follow-up approximately every 12 weeks after the end of treatment (EOT) for at least three years from the first dose of pelabresib and for at least two years following the last dose of pelabresib, whichever is longer. Long-term follow-up will continue until death, withdrawal from the study, loss to follow-up, or completion of the follow-up period, whichever occurs first. Safety follow-up and long-term follow-up visits will include assessment for leukemic transformation, which will be conducted throughout the study and for up to two years after treatment. The study will continue until all participants complete long-term follow-up or until access to pelabresib is ensured through a post-trial access program or reimbursement of pelabresib in Japan becomes available. Japanese safety confirmation will be determined according to the decision rule. The starting dose is 125 milligrams once daily (QD), and no dose escalation or de-escalation for safety confirmation is planned in this study. Initially, three participants will receive 125 milligrams QD of pelabresib as an add-on to ruxolitinib. The dose-limiting toxicity (DLT) evaluation period for Japanese safety confirmation is 21 days (one cycle). Interventions Pelabresib Ruxolitinib Eligibility Criteria Key Inclusion Criteria: * Participants have diagnosis of primary myelofibrosis (PMF), post-polycythemia vera MF (Post-PV MF) or post-essential thrombocythemia MF (Post-ET MF) according to the International Consensus Classification (ICC) for Myeloid Neoplasms and Acute Leukemias 2022. * DIPSS risk category intermediate-1, intermediate-2 or high-risk at screening. * Participants currently treated with ruxolitinib monotherapy AND who are likely to benefit from the addition of pelabresib to ruxolitinib in the opinion of the investigator. * Receiving ruxolitinib at a stable dose (5 to 25 mg BID) for at least 8 weeks prior to the first dose of pelabresib. * Palpable spleen (spleen length below left costal margin [LCM] must be recorded) or documented splenomegaly by MRI or CT (image report must be recorded) at screening. * Platelet count ≥ 100 × 10^9 ...

April 30, 2026

Novartis announces new API facility in Morrisville, North Carolina; end-to-end US production

Novartis announces new API facility in Morrisville, North Carolina; end-to-end US production Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility | Novartis At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced technology platforms in US – a first in company’s history ...

April 30, 2026

Sandra Schärer (Ypsomed) referiert über Kombinationsprodukte am Trinity College Dublin; Über 500 Teilnehmer erwartet.

Sandra Schärer (Ypsomed) referiert über Kombinationsprodukte am Trinity College Dublin; Über 500 Teilnehmer erwartet. 28th Annual QP Forum - Ypsomed 12.05.2026 - 12.05.2026 Edmund Burke Theatre, Arts Building at Trinity College, Dublin Das 28. Annual QP Forum findet am 12. Mai 2026 am Trinity College Dublin statt und bringt mehr als 500 Qualified Persons und Branchenexperten zusammen, um Erfahrungen auszutauschen und über aktuelle Anforderungen informiert zu bleiben. Das Programm umfasst Vorträge und Podiumsdiskussionen mit führenden Vertretern aus Industrie und Wissenschaft und behandelt Themen wie den Einfluss von KI auf cGMP, Trends in pharmazeutischen Lieferketten sowie praktische Herausforderungen im Arbeitsalltag. Sandra Schärer von Ypsomed wird zu Kombinationsprodukten referieren und Einblicke in zentrale Aspekte für Qualified Persons geben, die an der Schnittstelle von Arzneimitteln und Medizinprodukten arbeiten. Nehmen Sie unbedingt an der Session um 12:00 Uhr teil, um praxisnahe Einblicke in die Anforderungen an Kombinationsprodukte zu erhalten. Jetzt registrieren Unsere Referentin auf der Konferenz Sandra Schärer Regulatory Affairs Manager Thema: Kombinationsprodukte Datum & Uhrzeit: 12. Mai, 12 Uhr Zurück ...

April 30, 2026

AOK-Bundesverband und aQua-Institut veröffentlichen Qualitätsindikatoren zur Behandlung chronischer Schmerzen in Deutschland; Strukturiertes Langzeitmanagement in Hausarztpraxen

AOK-Bundesverband und aQua-Institut veröffentlichen Qualitätsindikatoren zur Behandlung chronischer Schmerzen in Deutschland; Strukturiertes Langzeitmanagement in Hausarztpraxen AOK und aQua veröffentlichen Qualitätsindikatoren zur Behandlung chronischer Schmerzen | Presse und Politik AOK und aQua veröffentlichen Qualitätsindikatoren zur Behandlung chronischer Schmerzen Neuer QISA-Band umfasst 13 Indikatoren zur adäquaten Behandlung nicht tumorbedingter Schmerzen. Drei Indikatoren zur Verordnung von Opioiden Insgesamt 16 Themenbände mit mehr als 200 Indikatoren Mit einem neuen Themenband zur adäquaten Behandlung von chronischen, nicht tumorbedingten Schmerzen haben der AOK-Bundesverband und das Göttinger aQua-Institut heute ihr System von Qualitätsindikatoren für die ambulante Versorgung (QISA) ergänzt. Die Publikation umfasst insgesamt 13 Indikatoren, die überwiegend auf die Verbesserung der Prozessqualität der Behandlung abzielen, aber auch Aspekte der Ergebnis- und Strukturqualität beleuchten. Nach Einschätzung von Expertinnen und Experten liegt bei chronischen Schmerzen oftmals eine Unter- oder Fehlversorgung vor, die eine weitere Chronifizierung fördert und im Ergebnis einen hohen volkswirtschaftlichen Schaden verursacht. ...

April 30, 2026